Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Buisson

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
United European Gastroenterology Journal|August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational SurveyAna Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2025
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre StudyMathilde Osty, Romain Altwegg, Mélanie Serrero, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Journal of Crohn'S & Colitis|March 29, 2023
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAIDAurelien Amiot, Sayma Chaibi, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 28, 2025
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitisSailish Honap, Joelle St-Pierre, Michael Colwill, et al.
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2026
Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic eraMatthieu Allez, Michiel T J Bak, Sofia Brand, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
United European Gastroenterology Journal|August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational SurveyAna Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2025
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre StudyMathilde Osty, Romain Altwegg, Mélanie Serrero, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Journal of Crohn'S & Colitis|March 29, 2023
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAIDAurelien Amiot, Sayma Chaibi, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 28, 2025
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitisSailish Honap, Joelle St-Pierre, Michael Colwill, et al.
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2026
Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic eraMatthieu Allez, Michiel T J Bak, Sofia Brand, et al.
Pageof 17